X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will enable Nouscom to continue advancing and expanding its wholly owned clinical pipeline including readout from its ongoing randomized Phase 2 clinical trial for NOUS-209, an off-the-shelf cancer vaccine for dMMR/MSI Metastatic Colorectal Cancer.
Lead Product(s): NOUS-209,Pembrolizumab
Therapeutic Area: Oncology Product Name: NOUS-209
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Angelini Ventures
Deal Size: $82.1 million Upfront Cash: Undisclosed
Deal Type: Series C Financing March 21, 2024
Details:
The proceeds will be used to continue advancing and expanding Nouscom’s wholly owned clinical pipeline, including NOUS-209 (GAd20-209-FSP), an off-the-shelf cancer vaccine targeting 209 shared neoantigens.
Lead Product(s): GAd20-209-FSP,MVA-209-FSP,Pembrolizumab
Therapeutic Area: Oncology Product Name: NOUS-209
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Andera Partners
Deal Size: $72.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing November 14, 2023
Details:
Nous-209 is based on a heterologous prime/boost regimen composed of the Great Ape Adenovirus GAd20-209-FSP used for priming and Modified Vaccinia virus Ankara MVA-209-FSP used for boosting.
Lead Product(s): GAd20-209-FSP,MVA-209-FSP,Pembrolizumab
Therapeutic Area: Oncology Product Name: Nous-209
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: ProBioGen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2023
Details:
NOUS-209 (GAd20-209-FSP) is an off-the-shelf cancer immunotherapy for MSI-H tumors. MSI-H tumors are characterized by a defective DNA mismatch repair system, which generates highly immunogenic neoantigens called frame shift peptides that are not present in healthy tissue.
Lead Product(s): GAd20-209-FSP,MVA-209-FSP,Pembrolizumab
Therapeutic Area: Oncology Product Name: NOUS-209
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: MSD Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 05, 2023
Details:
NOUS-209 (GAd-209-FSP) is an off-the-shelf cancer immunotherapy for Microsatellite Instable High (MSI-H) tumors, generates highly immunogenic neoantigens called frame shift peptides (FSP) that are not present in healthy tissue.
Lead Product(s): GAd-209-FSP,Pembrolizumab
Therapeutic Area: Oncology Product Name: NOUS-209
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2022
Details:
This mechanism was characterized in preclinical model of colorectal cancer and confirmed in Phase 1b trial in gastrointestinal patients with (MSI-H) tumors who saw durable clinical responses when treated with NOUS-209(GAd-209-FSP) in combination with anti-PD1.
Lead Product(s): GAd-209-FSP,Pembrolizumab
Therapeutic Area: Oncology Product Name: NOUS-209
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2022
Details:
NOUS-209 (GAd-209-FSP), is an off-the-shelf cancer vaccine targeting 209 shared neoantigens, in combination with anti-PD-1 checkpoint inhibitor pembrolizumab, for the treatment of deficiency in Mismatch Repair/Microsatellite Instable HigH unresectable or metastatic tumors.
Lead Product(s): GAd-209-FSP,Pembrolizumab
Therapeutic Area: Oncology Product Name: NOUS-209
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2022
Details:
NOUS-209 (GAd-209-FSP) is an off-the-shelf immunotherapy for Microsatellite Instable High (MSI-H) tumors. MSI-H tumors are characterized by a defective DNA mismatch repair system, which generates highly immunogenic frame shift peptides that are not found on healthy tissue.
Lead Product(s): GAd-209-FSP,Pembrolizumab
Therapeutic Area: Oncology Product Name: NOUS-209
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 27, 2022
Details:
NOUS-PEV will be investigated in the study as a potential treatment for patients with either locally advanced 1L melanoma or 1L non-small cell lung cancer (NSCLC).
Lead Product(s): NOUS-PEV
Therapeutic Area: Oncology Product Name: NOUS-PEV
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
